Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Discover Emerging Technologies Driving the Future of Global Markets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting... see more

Recent & Breaking News (CSE:DTC)

Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics

Newsfile September 12, 2023

Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid

Newsfile September 5, 2023

Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano

Newsfile July 18, 2023

RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Newsfile July 5, 2023

Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Newsfile July 4, 2023

Defence Patent Portfolio at the Forefront of Success

Newsfile June 28, 2023

Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published

Newsfile June 20, 2023

Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope

Newsfile June 16, 2023

Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer

Newsfile June 6, 2023

Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

Newsfile May 26, 2023

Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma

Newsfile May 24, 2023

BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment

Newsfile May 10, 2023

BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News

Newsfile May 4, 2023

Canadian biopharma company ready to submit investigational new drug filing

Jonathon Brown May 3, 2023

Defence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing

Newsfile May 2, 2023

USPTO Grants Trademark Registration for Defence Therapeutics(R)

Newsfile April 27, 2023

This “vaccine enhancer’s” new patent gives it even wider coverage

Jonathon Brown April 24, 2023

Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology

Newsfile April 24, 2023

Defence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer

Newsfile April 17, 2023

RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

Newsfile April 11, 2023

Podcasts